"Agaplesion Markus Krankenhaus, Klinik für Gynäkologie und Geburtshilfe, Brustzentrum"
Welcome,         Profile    Billing    Logout  
 5 Trials 
8 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Thill, Marc
PADMA, NCT03355157 / 2016-004482-89: A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - Study).

Recruiting
4
150
Europe
Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
German Breast Group, Pfizer, AMS Advanced Medical Services GmbH
Metastatic Breast Cancer
03/23
03/23
CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

Not yet recruiting
4
1000
Europe
Ribociclib
Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals
Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer
08/24
08/26
EMBER-3, NCT04975308: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Recruiting
3
800
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/23
09/26
SASCIA, NCT04595565: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Checkmark Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment.
Checkmark Phase III postneoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA
Checkmark Evaluation of sacituzumab govitecan (SG) in patients (pts) with metastatic triple negative breast cancer (mTNBC) in the phase 3 ASCENT study, after previous neoadjuvant / adjuvant chemotherapy
Checkmark [VIRTUAL] Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).
Checkmark [VIRTUAL] Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.
More
Recruiting
3
1200
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
12/26
12/28
Keyriched-1, NCT03988036: A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype

Checkmark Keyriched-1- A prospective, multicenter, open label, neoadjuvant phase ii single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsi…
Checkmark KEYRICHED-1 - A prospective, multicenter, open label, neoadjuvant phase II single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrins…
Recruiting
2
46
Europe
Pembrolizumab, Keytruda®, Trastuzumab Biosimilar ABP 980, Trazimera®, Pertuzumab, Perjeta®
West German Study Group, Merck Sharp & Dohme Corp., NanoString Technologies, Inc.
Breast Cancer
08/21
12/21
PULSE, NCT03975855: Evaluation of NeoNavia® Biopsy System in Axillary Lymph Nodes

Checkmark [VIRTUAL] One size fits all? Novel pulse biopsy platform offers improved needle control, high tissue yield and multiple needle options – pre-clinical results
Active, not recruiting
N/A
140
Europe
NeoNavia® Biopsy System
NeoDynamics AB
Breast Cancer
06/21
06/21
NCT05458739: The ClearCoast™ Magnetic Resonance Outcome PMS Study

Recruiting
N/A
93
Europe
ClearCoast MR System
Clear Cut Medical Ltd.
Breast Cancer
01/23
07/23
Brandi, Christiane
Keyriched-1, NCT03988036: A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype

Checkmark Keyriched-1- A prospective, multicenter, open label, neoadjuvant phase ii single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsi…
Checkmark KEYRICHED-1 - A prospective, multicenter, open label, neoadjuvant phase II single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrins…
Recruiting
2
46
Europe
Pembrolizumab, Keytruda®, Trastuzumab Biosimilar ABP 980, Trazimera®, Pertuzumab, Perjeta®
West German Study Group, Merck Sharp & Dohme Corp., NanoString Technologies, Inc.
Breast Cancer
08/21
12/21

Download Options